뒤로
Virpax Pharmaceuticals Inc (VRPX) 수입
VRPX 주가 차트
VRPX 수입
Virpax Pharmaceuticals Inc
$0
0%
$0
종가: Mar 26, 16:00:00 GMT-4
$0
0%
$0
애프터마켓: Mar 26, 20:00:00 GMT-4
최신 수익 결과: Q4 '24
보고됨: 2025-03-03
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
VRPX의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Virpax Pharmaceuticals Inc VRPX의 지난 분기 매출 실적은 어땠나요?
Virpax Pharmaceuticals Inc의 매출 추정치는 얼마인가요?
Virpax Pharmaceuticals Inc의 수익 품질 점수는 얼마인가요?
Virpax Pharmaceuticals Inc는 언제 수익을 보고하나요?
Virpax Pharmaceuticals Inc의 예상 수익은 얼마인가요?
Virpax Pharmaceuticals Inc은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$0.0001
시가
$0.021
일일 범위
$0.0001 - $0.021
52주 범위
$0.0001 - $2.1
거래량
51
평균 거래량
1.1K
배당수익률
--
EPS(TTM)
-5.29
시가총액
$128
VRPX란 무엇인가요?
Virpax Pharmaceuticals, Inc. is a preclinical stage biopharmaceutical company, which engages in the development of branded, non-addictive pain management products. The company is headquartered in Berwyn, Pennsylvania and currently employs 2 full-time employees. The company went IPO on 2021-02-17. The firm is focused on developing novel and proprietary drug delivery systems across various pain indications. Its drug-delivery systems and drug-releasing technologies being developed are focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system (CNS) disorders to enhance patients’ quality of life. Its portfolio consists of multiple preclinical stage product candidates: Epoladerm, Probudur, Envelta, AnQlar and NobrXiol. Probudur is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain. Envelta is an intranasal molecular envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. The NobrXiol is being developed for the nasal delivery of a pharmaceutical grade cannabidiol (CBD) for the management of rare pediatric epilepsy.